z-logo
open-access-imgOpen Access
Resistance to Second-Generation HIV-1 Maturation Inhibitors
Author(s) -
Emiko Urano,
Uddhav Timilsina,
Justin A. Kaplan,
Sherimay D. Ablan,
Dibya Ghimire,
Phuong Pham,
Nishani Kuruppu,
Rebecca Mandt,
Stewart R. Durell,
Theodore J. Nitz,
David E. Martin,
Carl Wild,
Ritu Gaur,
Eric O. Freed
Publication year - 2018
Publication title -
journal of virology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.617
H-Index - 292
eISSN - 1070-6321
pISSN - 0022-538X
DOI - 10.1128/jvi.02017-18
Subject(s) - biology , microbiology and biotechnology , capsid , mutant , genetics , protease , biochemistry , virus , enzyme , gene
HIV-1 maturation inhibitors are a class of small-molecule compounds that block a late step in the viral protease-mediated processing of the Gag polyprotein precursor, the viral protein responsible for the formation of virus particles. The first-in-class HIV-1 maturation inhibitor bevirimat was highly effective in blocking HIV-1 replication, but its activity was compromised by naturally occurring sequence polymorphisms within Gag. Recently developed bevirimat analogs, referred to as “second-generation” maturation inhibitors, overcome this issue. To understand more about how these second-generation compounds block HIV-1 maturation, here we selected for HIV-1 mutants that are resistant to these compounds. Selections were performed in the context of two different subtypes of HIV-1. We identified a small set of mutations at highly conserved positions within the capsid and spacer peptide 1 domains of Gag that confer resistance. Identification and analysis of these maturation inhibitor-resistant mutants provide insights into the mechanisms of resistance to these compounds.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom